I'd much rather have them take the time to make sure that everything has been analyzed in the way that presents the data in the best light for whichever groups are most helped by the drug, rather than have them rush the data out with either inaccuracies or people saying "But why didn't you compare this data to that data?"
Two companies that I know of had share prices torpedoed not on bad data, but on bad (rushed) analysis. I'm glad IPIX isn't making that mistake.
(3)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links